Viropharma (VPHM) Shares Sink Amid Cinryze Data; Stifel Nicolaus Weighs In
Tweet
Share
E-mailGet Alerts VPHM Hot Sheet
Price: $49.96 --0%
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
Shares of Viropharma (Nasdaq: VPHM) have tumbled nearly 7 percent Tuesday following the release of data on the company's subcutaneous Cinryze(R) with recombinant human hyaluronidase. The stock last traded at $30.50.
Stifel Nicolaus' Stephen Willey said in an earlier note Viropharma will likely need to show more dose-ranging data on the product's effectiveness. While the analyst noted 2,000-unit sub-Q data validates utilization of rHuPH20 usage with Cinryze, he warned logistical issues may pop up related to manufacturing capacity and cost before a twice-per-week dosing could be a feasible option. Willey also suggested the data confirms an unformulated sub-Q1 C1 inhibitor would not be a viable treatment option.
Despite the cautious comments, Stifel Nicolaus and Willey maintain a Buy rating and $42 price target on shares of Viropharma.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Viropharma.
Stifel Nicolaus' Stephen Willey said in an earlier note Viropharma will likely need to show more dose-ranging data on the product's effectiveness. While the analyst noted 2,000-unit sub-Q data validates utilization of rHuPH20 usage with Cinryze, he warned logistical issues may pop up related to manufacturing capacity and cost before a twice-per-week dosing could be a feasible option. Willey also suggested the data confirms an unformulated sub-Q1 C1 inhibitor would not be a viable treatment option.
Despite the cautious comments, Stifel Nicolaus and Willey maintain a Buy rating and $42 price target on shares of Viropharma.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Viropharma.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Hayward Holdings (HAYW) Reiterated at Buy by Stifel on Top-Tier Fundamental Growth Profile
- salesforce.com (CRM) PT Raised to $300 at TD Cowen
Create E-mail Alert Related Categories
Analyst Comments, Corporate NewsRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
